Can a cancer drug boost quality of life for the sickest lung cancer patients?
NCT ID NCT05589818
First seen Jun 20, 2026 · Last updated Jun 20, 2026
Summary
This study is testing whether the immunotherapy drug pembrolizumab can improve quality of life for people with advanced non-small cell lung cancer who are not healthy enough for standard treatments. The trial will enroll 45 patients who have not had prior cancer therapy and have a poor performance status (ECOG 2 or 3). Participants will receive pembrolizumab every three weeks, and their quality of life will be measured using a standard questionnaire over 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mount Sinai Hospital
RECRUITINGNew York, New York, 10029, United States
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (a drug that helps the immune system fight cancer)
What this could lead to
If successful, this could show that pembrolizumab improves quality of life for people with advanced lung cancer who are too weak for standard treatments.
What could go wrong
This is a small, early-phase study with no comparison group, so results may not be conclusive. Pembrolizumab can cause immune-related side effects like inflammation of the lungs, colon, or skin.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.